|
Diabetes Mellitus
|
0.400 |
AlteredExpression
|
group |
BEFREE |
2) In contrast to previous studies, the presence of diabetes does not influence adiponectin serum levels after correction for BMI.
|
15239024 |
2004 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin (ACRP30), an adipocyte-secreted protein encoded by the APM1 gene, is known to modulate insulin sensitivity and glucose homeostasis, those effects protecting obese mice from diabetes.
|
12354786 |
2002 |
|
Diabetes Mellitus
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Adiponectin values did not differ among these two genotypes even when categorized based on their diabetes status (normal glucose tolerance Pro12Pro 7.9 vs. Pro12Ala 7.7 microg/ml, P = 0.994; diabetes Pro12Pro 4.7 vs. Pro12Ala 5.4 microg/ml, P = 0.622).
|
17335469 |
2007 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin has been associated with low diabetes risk.
|
17416799 |
2007 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin has demonstrated insulin-sensitizing, antiatherogenic, and anti-inflammatory properties, and may be an important risk factor for coronary heart disease and diabetes.
|
17618943 |
2007 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin (Adipo), an adipocyte hormone involved in the regulation of glucose and lipid metabolism, has already been identified as a potential therapeutic target for the treatment of diabetes.
|
17868184 |
2007 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin modulates lipid metabolism and liver injury in nonalcoholic fatty liver disease (NAFLD) even in the absence of obesity, dyslipidemia, and diabetes.
|
18311774 |
2008 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin is an abundant circulating adipocyte-derived cytokine that has beneficial effects on disorders accompanying diabetes.
|
18639522 |
2008 |
|
Diabetes Mellitus
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Adiponectin SNP sites were investigated at +45 of exon 2 and at +276 of intron 2; these sites have been thought to be associated with diabetes or insulin resistance.
|
19484180 |
2009 |
|
Diabetes Mellitus
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Adiponectin is an adipocyte-secreted, insulin-sensitizing hormone the circulating levels of which are reduced in conditions of insulin resistance and diabetes.
|
19855092 |
2010 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin plays a pivotal role in the pathogenesis of diabetes and is considered to be involved in various pathological conditions associated with diabetes; however, its role in wound repair is unknown.
|
22904306 |
2012 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin (AdipoQ) plays an important role in the pathogenesis of diabetes mellitus and is considered as an important candidate gene for type 2 diabetes mellitus (T2DM).
|
23653335 |
2013 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin, an adipokine that is reduced in individuals with obesity and diabetes, has been characterized both as a negative regulator or permissive factor in cardiac hypertrophy.
|
26196305 |
2015 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin is a protein hormone with a major regulatory role in diabetes and obesity; however, its role in the CNS has not been studied yet.
|
26247729 |
2015 |
|
Diabetes Mellitus
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Adiponectin (ADP) polymorphisms associated with diabetes mellitus in several populations.
|
26616148 |
2015 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin, an adipocyte-derived cytokine, has many beneficial effects on metabolic disorders such as diabetes, obesity, hypertension, and dyslipidemia.
|
29145717 |
2017 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin is a fat tissue-derived adipokine with beneficial effects against diabetes, cardiovascular diseases, and cancer.
|
29991592 |
2018 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin homolog novel osmotin protects obesity/diabetes-induced NAFLD by upregulating AdipoRs/PPARα signaling in ob/ob and db/db transgenic mouse models.
|
30473057 |
2019 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin has also β cell protective effects and may prevent the development of diabetes.
|
30857216 |
2019 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin, an adipokine secreted by adipocytes, exerts favorable effects in the milieu of diabetes and metabolic syndrome through its anti-inflammatory, antifibrotic, and antioxidant effects.
|
30974901 |
2019 |
|
Diabetes Mellitus
|
0.400 |
Biomarker
|
group |
BEFREE |
Adiponectin is an adipokine that improves insulin sensitivity in obesity-related metabolic disorders, including diabetes, but its efficacy is unknown.
|
31048658 |
2019 |
|
Diabetes Mellitus
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A common variant in the CLDN7/ELP5 locus predicts adiponectin change with lifestyle intervention and improved fitness in obese individuals with diabetes.
|
25759378 |
2015 |
|
Diabetes Mellitus
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A low adiponectin level is a significant risk factor of diabetes mellitus and cardiovascular disease.
|
29287218 |
2018 |
|
Diabetes Mellitus
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A novel heterozygous T deletion at position 186 in exon 2 of ADIPOQ, causing a frameshift at codon 62 and leading to a premature termination at codon 168 (p.Gly63ValfsX106), was found in two individuals with diabetes.
|
19178518 |
2009 |
|
Diabetes Mellitus
|
0.400 |
AlteredExpression
|
group |
BEFREE |
AdipoR1 and adiponectin expression was associated in lean (r=0.943, P<0.005) and obese non-diabetic patients (r=0.74, P<0.01), whereas a positive correlation between adipoR2 and adiponectin expression was only found in the presence of diabetes (r=0.883, P<0.002).
|
16756736 |
2006 |